Pacific Biosciences of California, Inc.(PACB)

$1.35—

Chart

Pacific Biosciences of California, Inc.(PACB)

NASDAQ

$1.35—

Chart Studio

PACB(PACB)

PACB

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.13

Nov 3, 2026 · Reports after close

Revenue Estimate

$44M

Analyst Sentiment

Wall St. Consensus

Hold

18 analysts·Moderate coverage

Score

9 Buy (50%)8 Hold (44%)1 Sell (6%)

Rating Breakdown

Strong Buy

00%

Buy

950%

Hold

844%

Sell

16%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

-25.9%

Consensus

$1.00

-25.9%

Bull

$1.00

-25.9%

12-Month Target Range18 analysts

$1.00$1.00$1.00

Current $1.35Consensus

Current Price

$1.35

Above Consensus

$0.35

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+15.31%

EPS—

FY2028

Rev+16.60%

EPS—

FY2029

Rev+13.84%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$158M	$182M	$213M	$242M	$277M
Low	$155M	$178M	$204M	$232M	$266M
High	$161M	$187M	$221M	$252M	$288M
EBITDA Avg	$-133M	$-154M	$-179M	$-204M	$-233M
Low	$-136M	$-157M	$-186M	$-213M	$-243M
High	$-131M	$-150M	$-172M	$-196M	$-224M
EBIT Avg	$-158M	$-182M	$-213M	$-242M	$-277M
Low	$-161M	$-187M	$-221M	$-252M	$-288M
High	$-155M	$-178M	$-204M	$-232M	$-266M
Net Income Avg	$-136M	$-139M	$-114M	$-76M	$-63M
Low	$-143M	$-148M	$-124M	$-81M	$-66M
High	$-129M	$-133M	$-82M	$-72M	$-60M
EPS Avg	$-0.45	$-0.47	$-0.36	$-0.26	$-0.21
Low	$-0.48	$-0.49	$-0.41	$-0.27	$-0.22
High	$-0.43	$-0.44	$-0.27	$-0.24	$-0.20
Analysts (Rev / EPS)	4 / 3	4 / 4	5 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$39M	$43M	$43M	$44M	$47M	$50M	$50M	$50M
Low	$38M	$41M	$41M	$42M	$44M	$47M	$48M	$48M
High	$40M	$45M	$44M	$46M	$48M	$52M	$52M	$52M
EBITDA Avg	$-33M	$-36M	$-36M	$-37M	$-39M	$-42M	$-42M	$-42M
Low	$-33M	$-38M	$-37M	$-39M	$-41M	$-44M	$-44M	$-44M
High	$-32M	$-34M	$-34M	$-36M	$-37M	$-40M	$-40M	$-40M
EBIT Avg	$-39M	$-43M	$-43M	$-44M	$-47M	$-50M	$-50M	$-50M
Low	$-40M	$-45M	$-44M	$-46M	$-48M	$-52M	$-52M	$-52M
High	$-38M	$-41M	$-41M	$-42M	$-44M	$-47M	$-48M	$-48M
Net Income Avg	$-41M	$-41M	$-36M	$-37M	$-36M	$-37M	$-31M	$-37M
Low	$-44M	$-44M	$-38M	$-39M	$-38M	$-39M	$-33M	$-39M
High	$-39M	$-39M	$-34M	$-35M	$-34M	$-35M	$-29M	$-35M
EPS Avg	$-0.13	$-0.13	$-0.12	$-0.12	$-0.12	$-0.12	$-0.10	$-0.12
Low	$-0.14	$-0.14	$-0.12	$-0.12	$-0.12	$-0.12	$-0.11	$-0.13
High	$-0.13	$-0.13	$-0.11	$-0.11	$-0.11	$-0.11	$-0.09	$-0.11
Analysts (Rev / EPS)	3 / 3	3 / 3	1 / 1	1 / 1	1 / 1	1 / 1	1 / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

Apr 14, 2026Barclays

PacBio price target lowered to $1 from $1.50 at Barclays

Target:$1.00

-31.0%from $1.45

Aug 8, 2025Bernstein

PacBio price target raised to $1.70 from $1.50 at Bernstein

Target:$1.70

+27.3%from $1.33

Jun 25, 2025Barclays

PacBio price target lowered to $1.50 from $2 at Barclays

Target:$1.50

+23.0%from $1.22

Jun 3, 2024Jefferies

Jefferies Starts Pacific Biosciences of California (PACB) at Buy

Target:$4.00

+123.5%from $1.79

May 13, 2024Morgan Stanley

PacBio price target lowered to $4 from $10 at Morgan Stanley

Target:$4.00

+102.5%from $1.98

May 13, 2024Piper Sandler

PacBio price target lowered to $2 from $6.50 at Piper Sandler

Target:$2.00

+13.0%from $1.77

May 10, 2024Barclays

PacBio price target lowered to $2 from $3 at Barclays

Target:$2.00

+16.3%from $1.72

Apr 18, 2024Goldman Sachs

Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral

Target:$2.50

+78.6%from $1.40

Apr 16, 2024Canaccord Genuity

PacBio price target lowered to $3.50 from $10 at Canaccord

Target:$3.50

+150.0%from $1.40

Nov 16, 2022Canaccord Genuity

Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14

Target:$14.00

+29.6%from $10.80

Aug 17, 2022Piper Sandler

Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler

Target:$7.50

-1.4%from $7.61

May 15, 2022Piper Sandler

Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler

Target:$6.00

+2.7%from $5.84

Jan 12, 2022Piper Sandler

PacBio Stock (PACB): $20 Price Target From Piper Sandler

Target:$20.00

+38.4%from $14.45

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance